<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2016-9-4-52-57</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-59</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Слезозаместительная терапия катионной эмульсией в комплексном лечении поверхностного точечного кератита у больных с гипотензивной терапией глаукомы</article-title><trans-title-group xml:lang="en"><trans-title>Tear replacement by cationic emulsion in complex therapy of superficial punctate keratitis in hypotensively medicated glaucoma patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Труфанов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Trufanov</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маложен</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Malozhen</surname><given-names>S. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крахмалева</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krakhmaleva</surname><given-names>D. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пивин</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pivin</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «НИИ глазных болезней»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>03</day><month>10</month><year>2018</year></pub-date><volume>9</volume><issue>4</issue><fpage>52</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Труфанов С.В., Маложен С.А., Крахмалева Д.А., Пивин Е.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Труфанов С.В., Маложен С.А., Крахмалева Д.А., Пивин Е.А.</copyright-holder><copyright-holder xml:lang="en">Trufanov S.V., Malozhen S.A., Krakhmaleva D.A., Pivin E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/59">https://roj.igb.ru/jour/article/view/59</self-uri><abstract><p>Цель - оценить эффективность слезозаместительной терапии катионной эмульсией в комбинированном лечении поверхностного точечного кератита (ПТК) у больных с глаукомой. Методы. В клиническое исследование вошли 28 пациентов (30 глаз) в возрасте от 50 до 84 лет (в среднем 67,1±7,2 года), с явлениями ПТК, составивших 1-ую группу, которые получали длительную (в среднем 9,5±6,6 лет) местную гипотензивную терапию глаукомы комбинацией препаратов. Контралатеральные глаза 26 пациентов, средний возраст которых был равен 67,6±7,1 годам, без признаков кератита с диагнозом глаукома и ее местным лечением составили 2-ю группу. Всем пациентам 1-ой группы в качестве базисной терапии ПТК местно назначали антигистаминный препарат, кератопротектор на основе дексапантенола и любрикант Катионорм. Пациенты 2 группы также получали слезозаместительную терапию препаратом Катионорм. Алгоритм обследования и контроля эффективности проводимой терапии включал биомикроскопию, тест Ширмера, пробу Норна, а также осмолярометрию. Результаты. Признаки «сухого глаза» с нарушением осмолярности слезы, снижением показателей пробы Норна и теста Ширмера были выявлены у всех пациентов как на глазах с проявлениями ПТК, так и без таковых. У больных с сопутствующим синдромом «сухого глаза» на фоне комплексной терапии, включающей слезозаместительный препарат нового поколения Катионорм, отмечалось повышение стабильности слёзной пленки (повышение значений пробы Норна с 5,5±1.8 до 8,5±2.1 с и с 7,7±1.4 до 8,8±2.2 с в 1-ой и 2-ой группе соответственно, р&lt;0,05) и улучшение показателей теста Ширмера (с 6,3±2.1 до 8.3±3,7 мм и с 8,7±3,7 до 9,1±3,8 мм в 1-ой и 2-ой группе соответственно, р&lt;0,05), снижение повышенных показателей осмолярности как в 1-ой, так и 2-ой группе, р&lt;0,05. Субъективная симптоматика в 1-ой группе изменилась после 3 месяцев лечения с 3,4 до 0,6 балла. Тяжесть ПТК до начала лечения в среднем составляла 4,2±2,3 балла, через 1, 2, 3 месяца - 1,2±0,9, 0,23±0.5 и 0,1±0,3 баллов соответственно. Заключение. На основании данных проведенного исследования Катионорм может считаться слезозаместительным препаратом выбора в длительной комплексной терапии глаукомы при нарушении стабильности слезной пленки и выявлении симптомов ПТК // Российский офтальмологический журнал, 2016; 4: 52-57.</p></abstract><trans-abstract xml:lang="en"><p>Purpose. To evaluate the efficacy of lubricating cationic emulsion in the combined treatment of superficial punctate keratitis (SPK) of glaucoma patients. Material and methods. The clinical study involved an experimental group 1 of 28 patients (30 eyes) aged 50 to 84 (mean age 67.1 ± 7.2 years) with symptoms of SPK who received long-term (averagely 9.5 ± 6.6 years) topical hypotensive anti-glaucoma medication. The control group 2 consisted of 26 patients (mean age 67.6 ± 7.1 years) belonging to the experimental group: in this case, the contralateral eyes with topical anti glaucoma medication but no signs of keratitis were examined. The basic therapy for group 1 consisted of topical antihistamine, corneoprotector (dexpanthenol) and a new generation lubricant, Cationorm. Group 2 was also treated with Cationorm. The testing procedures and efficiency monitoring included biomicroscopy, Schirmer test, Norn test and evaluation of tear film osmolarity. Results. Dry eye symptoms with disturbed tear film osmolarity and decreased values of Norn and Schirmer tests were detected in all patients both in the eyes with SPK manifestations and without them. Patients with concomitant dry eye syndrome who received complex therapy, including Cationorm, showed increased tear film stability: Norn sample values increased from 5.5 ± 1.8 to 8.5 ± 2.1 seconds and from 7.7 ± 1.4 to 8.8 ± 2.2 seconds in groups 1 and 2, respectively, p &lt; 0.05). Besides, the values of the Schirmer test improved from 6.3 ± 2.1 to 8.3 ± 3.7 mm and 8.7 ± 3.7 to 9.1 ± 3.8 mm in groups 1 and 2, respectively, p &lt; 0.05), and osmolarityrate decreased in both groups, p &lt; 0.05. Subjective symptoms in group 1 changed from 3.4 to 0.6 points after 3 months of treatment. The average severity of SPK, which amounted to 4.2 ± 2.3 points before treatment, dropped to 1.2 ± 0.9, 0.23 ± 0.5 and 0.1 ± 0.3 points respectively after 1, 2 and 3 months. Conclusion. The study shows that Cationorm can be considered as a tear replacement lubricant of choice in the complex therapy of superficial punctate keratitis and dry eye symptoms in chronically medicated glaucoma patients // Russian Ophthalmological Journal, 2016; 4: 52-7. doi: 10.21516/2072-0076-2016-9-4-52-57.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>поверхностный точечный кератит</kwd><kwd>синдром «сухого глаза»</kwd><kwd>глаукома</kwd><kwd>консерванты</kwd><kwd>тест Ширмера</kwd><kwd>проба Норна</kwd><kwd>осмолярометрия</kwd><kwd>кератопротекторы</kwd><kwd>слезозаместительная терапия</kwd><kwd>Катионорм</kwd><kwd>superficial punctate keratitis</kwd><kwd>dry eye syndrome</kwd><kwd>glaucoma</kwd><kwd>preservatives</kwd><kwd>Schirmer test</kwd><kwd>Norn test</kwd><kwd>tear film osmolarity</kwd><kwd>Cationorm</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Marquis R.E., Whitson J.T. Management of glaucoma: focus on pharmacological therapy. Drugs and Aging. 2005; 22(1): 1-21.</mixed-citation><mixed-citation xml:lang="en">Marquis R.E., Whitson J.T. Management of glaucoma: focus on pharmacological therapy. Drugs and Aging. 2005; 22(1): 1-21.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Camras C.B., Toris C.B., Tamesis R.R. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs and Aging, 1999; 15(5): 377-88.</mixed-citation><mixed-citation xml:lang="en">Camras C.B., Toris C.B., Tamesis R.R. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs and Aging, 1999; 15(5): 377-88.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Сафонова Т.Н., Федоров А.А., Забегайло А.О., Егорова Г.Б., Митичкина Т.С. Лечение синдрома «сухого глаза» при первичной глаукоме. Национальный журнал глаукома. 2015; 14 (4): 36-43.</mixed-citation><mixed-citation xml:lang="en">Сафонова Т.Н., Федоров А.А., Забегайло А.О., Егорова Г.Б., Митичкина Т.С. Лечение синдрома «сухого глаза» при первичной глаукоме. Национальный журнал глаукома. 2015; 14 (4): 36-43.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Saint Jean M., Debbasch C., Brignole F., et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000; 20: 85-94.</mixed-citation><mixed-citation xml:lang="en">De Saint Jean M., Debbasch C., Brignole F., et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000; 20: 85-94.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Burstein N.L. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980; 25: 15-30.</mixed-citation><mixed-citation xml:lang="en">Burstein N.L. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980; 25: 15-30.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Burstein N.L. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK. 1985; 104: 402-9.</mixed-citation><mixed-citation xml:lang="en">Burstein N.L. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK. 1985; 104: 402-9.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Егорова Г.Б., Федоров А.А., Митичкина Т.С., Шамсутдинова А.Р., Сафонова Т.Н. Влияние слезозаместительной и корнеопротекторной терапии на состояние глазной поверхности при синдроме «сухого глаза». Клиническая Офтальмология. 2015; 15(1): 15-21.</mixed-citation><mixed-citation xml:lang="en">Егорова Г.Б., Федоров А.А., Митичкина Т.С., Шамсутдинова А.Р., Сафонова Т.Н. Влияние слезозаместительной и корнеопротекторной терапии на состояние глазной поверхности при синдроме «сухого глаза». Клиническая Офтальмология. 2015; 15(1): 15-21.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wilcon L.A. To preserve or not to preserve, is that the question? Br. J. Ophthalmol. 1996; 80: 583-4.</mixed-citation><mixed-citation xml:lang="en">Wilcon L.A. To preserve or not to preserve, is that the question? Br. J. Ophthalmol. 1996; 80: 583-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C., Labbé A., Liang H., Pauly A., Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 2010; 29: 312-34.</mixed-citation><mixed-citation xml:lang="en">Baudouin C., Labbé A., Liang H., Pauly A., Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 2010; 29: 312-34.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fechtner R.D., Godfrey D.G., Budenz D., et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010; 29: 618-21.</mixed-citation><mixed-citation xml:lang="en">Fechtner R.D., Godfrey D.G., Budenz D., et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010; 29: 618-21.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman N.J. Impact of dry eye disease and treatment on quality of life. Current Opinion in Ophthalmology. 2010; 21(4): 310-6.</mixed-citation><mixed-citation xml:lang="en">Friedman N.J. Impact of dry eye disease and treatment on quality of life. Current Opinion in Ophthalmology. 2010; 21(4): 310-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23: 490-6.</mixed-citation><mixed-citation xml:lang="en">Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23: 490-6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Becquet F., Goldschild M., Moldovan M.S., et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998; 17: 419-25.</mixed-citation><mixed-citation xml:lang="en">Becquet F., Goldschild M., Moldovan M.S., et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998; 17: 419-25.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson F.M. Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol. 1979; 24: 57-88.</mixed-citation><mixed-citation xml:lang="en">Wilson F.M. Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol. 1979; 24: 57-88.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yalvac I.S., Gedikoglu G., Yaragöz Y., et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995; 73: 246-8.</mixed-citation><mixed-citation xml:lang="en">Yalvac I.S., Gedikoglu G., Yaragöz Y., et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995; 73: 246-8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Herreras J.M., Pastor J.C., Calonge M., et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992; 99: 1082-8.</mixed-citation><mixed-citation xml:lang="en">Herreras J.M., Pastor J.C., Calonge M., et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992; 99: 1082-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Burstein N.L. Preservative cytotoxic threshold for benzalkonium chloride and Chlorhexidine digluconate in cat and rabbit corneas. Invest. Ophthalmol. Vis Sci. 1980; 19: 308-13.</mixed-citation><mixed-citation xml:lang="en">Burstein N.L. Preservative cytotoxic threshold for benzalkonium chloride and Chlorhexidine digluconate in cat and rabbit corneas. Invest. Ophthalmol. Vis Sci. 1980; 19: 308-13.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Grant R.L., Acosta D. Prolonged adverse effects of benzalkonium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. Fundam Appl Toxicol. 1996; 33: 71-82.</mixed-citation><mixed-citation xml:lang="en">Grant R.L., Acosta D. Prolonged adverse effects of benzalkonium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. Fundam Appl Toxicol. 1996; 33: 71-82.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">De Jong C., Solwijk T., Kuppens E., et al. Topical timolol with and without benzalkonium chloride; epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1994; 232: 221-4.</mixed-citation><mixed-citation xml:lang="en">De Jong C., Solwijk T., Kuppens E., et al. Topical timolol with and without benzalkonium chloride; epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1994; 232: 221-4.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Servat J.J., Bernardino C.R. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011; 28: 267-282.</mixed-citation><mixed-citation xml:lang="en">Servat J.J., Bernardino C.R. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011; 28: 267-282.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pisella P.J., Pouloquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002; 86: 418-23.</mixed-citation><mixed-citation xml:lang="en">Pisella P.J., Pouloquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002; 86: 418-23.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bohn R.L., Gurwitz J.H., Yeomans S.M., et al. Which patients are treated for glaucoma? An observational analysis. J. Glaucoma. 2000; 9: 38-44.</mixed-citation><mixed-citation xml:lang="en">Bohn R.L., Gurwitz J.H., Yeomans S.M., et al. Which patients are treated for glaucoma? An observational analysis. J. Glaucoma. 2000; 9: 38-44.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gordon J., Johnson P.J. Fibronectin Study Group-discontinuation of topical ophthalmic medications promotes healing of non-healing corneal epithelial defects. Invest. Ophthalmol. Vis Sci. 1991; 32:.1071.</mixed-citation><mixed-citation xml:lang="en">Gordon J., Johnson P.J. Fibronectin Study Group-discontinuation of topical ophthalmic medications promotes healing of non-healing corneal epithelial defects. Invest. Ophthalmol. Vis Sci. 1991; 32:.1071.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Laflamme M.Y., Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can. J. Ophthalmol. 1988; 23: 174-6.</mixed-citation><mixed-citation xml:lang="en">Laflamme M.Y., Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can. J. Ophthalmol. 1988; 23: 174-6.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Miyata K., Amano S., Sawa M., Nishida T. A novel grading methods for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch. Ophthalmol. 2003; 121(11): 1537-9.</mixed-citation><mixed-citation xml:lang="en">Miyata K., Amano S., Sawa M., Nishida T. A novel grading methods for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch. Ophthalmol. 2003; 121(11): 1537-9.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C., Renard J.-P.l, Nordmann J.-P., et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2013; 23(1): 47-54.</mixed-citation><mixed-citation xml:lang="en">Baudouin C., Renard J.-P.l, Nordmann J.-P., et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2013; 23(1): 47-54.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Edelhauser H.F., Ubels J. The cornea and the sclera. In: Kaufman P.L., Alm A., eds. Adler’s Physiology of the Eye. 10th ed. St. Louis, MO: Mosby; 2003: 47-114.</mixed-citation><mixed-citation xml:lang="en">Edelhauser H.F., Ubels J. The cornea and the sclera. In: Kaufman P.L., Alm A., eds. Adler’s Physiology of the Eye. 10th ed. St. Louis, MO: Mosby; 2003: 47-114.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
